News

02/06/20	Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th REDWOOD CITY, Calif. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2019 financial results will be released after market close on Thursday, February 27, 2020 . Starting at 4:30 p.m.
01/13/20	Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States Agreement Includes an Option for Rituxan® Biosimilar REDWOOD CITY, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the Company has entered into a licensing agreement with Innovent Biologics , (Suzhou) Co., Ltd.,
01/03/20	Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference REDWOOD CITY, Calif. , Jan. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 38 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:00 a.m. PT , being held in San Francisco .